Key result
Recombinant human growth hormone administration significantly reduced myocardial norepinephrine release during physical exercise (from 180 to 99 ng/min; P<0.05) in idiopathic cardiomyopathy.
Why the study?
Does recombinant human growth hormone reduce myocardial sympathetic drive in patients with idiopathic dilated cardiomyopathy?
Population
7 patients with idiopathic dilated cardiomyopathy
Design
Case_series
Follow-up
3 months
Authors
Loading...
May support neurohormonal investigation in cardiomyopathy; leaves open clinical relevance pending controlled trials.
Does recombinant human growth hormone reduce myocardial sympathetic drive in patients with idiopathic dilated cardiomyopathy?
Absolute Event Rate: 99% vs 180%
p-value: p=< 0.05
Growth hormone administration in patients with idiopathic dilated cardiomyopathy reduces myocardial sympathetic drive and circulating aldosterone levels, suggesting potential neurohormonal deactivation benefits.
Brunella Capaldo (1998) studied idiopathic dilated cardiomyopathy (n=7). recombinant human growth hormone vs. Baseline was evaluated on Myocardial norepinephrine release in response to physical exercise (p=< 0.05). Recombinant human growth hormone administration significantly reduced myocardial norepinephrine release during physical exercise (from 180 to 99 ng/min; P<0.05) in idiopathic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: